Results 241 to 250 of about 19,226,899 (298)

Diagnostic value of PNI and MLR in cirrhotic patients with negative HBV DNA and positive HBV RNA:A nomogram--based evaluation model. [PDF]

Front Med (Lausanne)
Li M, Fang Y, Han Y, Li T, Liu Y, Chen L.   +5 more
europepmc   +1 more source

Factors Associated With Surface Antigen (HBsAg) Clearance in a Spanish Cohort of Chronic Hepatitis B Patients: Influence on the Long-Term Prognosis. [PDF]

J Med Virol
Gavilán P, Gavilán JC, Piserra-Lopez A.   +2 more
europepmc   +1 more source

Hypovitaminosis D-Induced Secondary Hyperparathyroidism With Concomitant Femoral Fracture in a Chronic Hepatitis B Patient: A Case Report. [PDF]

Clin Case Rep
Appati W, Hutton-Mensah KA, Aidoo L, Otchwemah NAS.   +3 more
europepmc   +1 more source

ALPS-HCC Score: A Dynamic Liver Stiffness Measurement-Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma. [PDF]

Liver Int
Huang Y, Yu H, Yang B, Jiang H, Hu C, Yu Q, Xi X, Li M, Lei Y, Wu B, Xie B, Ding H, Yang Y.   +12 more
europepmc   +1 more source

Treatment of chronic hepatitis D

Journal of Viral Hepatitis, 2007
Summary.  Despite recent advances in the treatment of chronic viral hepatitis, therapy of chronic hepatitis D is not yet satisfactory. The only option currently available is interferon‐α (IFN), whose efficacy is related to the dose and duration of treatment.
FARCI, PATRIZIA, CHESSA, LUCHINO, Balestrieri C, Serra G, Lai ME   +4 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Chronic hepatitis D—What is changing?

Journal of Viral Hepatitis, 2022
AbstractHepatitis D virus (HDV) infection is a chronic viral disease of the liver that is still largely considered to be incurable due to lack of effective treatment options. Without treatment, the risk for the development of advanced liver disease, cirrhosis and hepatocellular carcinoma is significantly high.
David Yardeni, Theo Heller, Christopher Koh   +2 more
openaire   +2 more sources

Treatment endpoints for chronic hepatitis D

Liver International, 2022
AbstractManagement of chronic hepatitis D (CHD) has entered a new era. In this new era, the virus entry inhibitor bulevirtide has received conditional approval as a treatment for compensated CHD. Three phase 3 studies with two new compounds are ongoing for the treatment of CHD.
Olga Metin, Müjdat Zeybel, Cihan Yurdaydin   +2 more
openaire   +2 more sources